Intracranial Aneurysm Market Poised to Double by 2032, Driven by Technological Innovation and Rising Disease Detection

Intracranial Aneurysm Market Revenue Analysis

The global intracranial aneurysm market was valued at USD 1.63 billion in 2024 and is expected to grow at a CAGR of 9.0% from 2025 to 2032, reaching USD 3.24 billion. Growth is primarily fueled by increasing prevalence of unruptured aneurysms, rising adoption of minimally invasive treatments, and rapid technological innovation across the neurovascular device landscape. Studies indicate that 3–5% of the global population has unruptured intracranial aneurysms, with women and older adults representing a growing proportion of diagnosed cases.

Endovascular coiling has emerged as the dominant treatment method, accounting for over 60–65% of procedures globally, and its adoption is expanding in Asia-Pacific and Latin America due to improved hospital access and specialist training. Additionally, the use of flow diverters is rising at over 12% annually, particularly for treating wide-neck or large aneurysms unsuitable for traditional coiling.

Access Key Market Insights: Request a Sample Report Now: https://www.snsinsider.com/sample-request/7935

Market Dynamics

The intracranial aneurysm market is supported by multiple growth drivers. Technological advancements, including AI-driven aneurysm detection software and robot-assisted navigation systems, are improving diagnosis and procedural precision. Enhanced availability of digital subtraction angiography (DSA) and 3D rotational angiography is strengthening case recognition and preoperative planning.

R&D investments are also accelerating, with leading players allocating 10–12% of annual revenue toward innovations in microcatheters, intrasaccular implants, and embolization systems. Over 30 neurovascular devices have received regulatory approval as of 2022, highlighting the robust innovation pipeline. Additionally, favorable reimbursement models in the U.S., Germany, and Japan are driving the adoption of novel devices like flow diverters, while emerging economies adopting universal health coverage (UHC) are gradually improving treatment access.

Drivers of Growth

The rising burden of neurovascular diseases is a primary market driver. In the U.S., approximately 30,000 people experience aneurysm rupture annually, underscoring the importance of early detection and treatment. Advanced imaging technologies such as 4D CTA and MRI angiography are enhancing early diagnosis, while next-generation flow diverters and embolic coils are enabling treatment of previously inoperable aneurysms.

R&D initiatives by companies like Balt, Sequent Medical, and NeuroVasc are expanding the product pipeline, with annual investment growth of 10–15% in leading firms. Regulatory support, such as the FDA Breakthrough Device Designation for the eCLIPs Bifurcation Flow Diverter in 2023, is accelerating market access. Public-private partnerships and neurovascular-focused investments exceeding USD 250 million over the past two years further contribute to increased device availability. Physician education and global neurovascular training programs are also enhancing procedural adoption.

Restraints Limiting Market Expansion

Despite strong growth, several factors may restrain market expansion. High procedural costs and device prices—flow diverters ranging from USD 15,000 to 25,000—limit adoption in low- and middle-income countries. A shortage of neurointerventionalists, particularly in rural and underdeveloped areas, restricts access to care. Basic neuroimaging such as CTA and DSA is scarce in these regions, resulting in delayed diagnoses and reduced eligibility for advanced interventions.

Safety concerns, including in-stent thrombosis or delayed rupture after device deployment, contribute to cautious clinical uptake. Reimbursement challenges persist as many national health systems are reluctant to cover high-cost devices without robust cost-effectiveness evidence. Regulatory delays in certain markets also prolong time-to-market for new innovations.

Segmentation Analysis

By product type, aneurysm therapeutic devices dominated the market in 2024 with a 64% share. These include detachable coils, embolization materials, flow diverters, and occlusion catheters, essential for both surgical and endovascular treatments. Flow diverters are emerging as the fastest-growing segment due to their ability to treat large, wide-neck aneurysms with fewer complications and lower retreatment rates.

By aneurysm type, saccular aneurysms accounted for more than 70% of treated cases in 2024, benefiting from established treatment guidelines and high prevalence. The rapid adoption of CT and MR angiography has improved early diagnosis and treatment outcomes. Mycotic aneurysms, though less common, are experiencing the highest growth due to rising infection-related complications, particularly in immunocompromised and elderly patients.

Endovascular coiling remained the most widely used treatment, representing 61% of procedures globally, owing to its minimally invasive nature, shorter hospital stays, and high safety profile. Flow diverters are the fastest-growing treatment option, preferred for large or complex aneurysms not suitable for coiling, as they modify blood flow and occlude aneurysms without entering the sac.

By end-user, hospitals held the largest market share in 2024 with 68% of procedures, driven by advanced imaging, hybrid operating rooms, and access to trained neurointerventionists. Specialty clinics are experiencing the highest CAGR due to increasing outpatient neurointerventional procedures, compact imaging systems, and insurance coverage expansion.

Enhanced Market Demand: Discover Thorough Trends and Insights in Our Complete Report: https://www.snsinsider.com/reports/intracranial-aneurysm-market-7935

Regional Insights

North America dominated the intracranial aneurysm market in 2024, supported by advanced healthcare infrastructure, high adoption of minimally invasive procedures, and favorable reimbursement models. The U.S. market was valued at USD 0.61 billion in 2024 and is projected to reach USD 1.18 billion by 2032 at a CAGR of 8.68%. High procedural volumes, FDA-approved devices, and a growing aging population contribute to this growth.

Europe is the second-largest market, driven by strong R&D investments, favorable reimbursement policies, and high procedural volumes in countries like Germany, France, and the UK. The Asia-Pacific region is the fastest-growing, with Japan, China, and India investing heavily in neuro-specialty hospitals, infrastructure, and universal healthcare initiatives.

Regulatory Approvals and Innovation

Recent device approvals highlight the market’s dynamic growth. MicroVention’s WEB 17 System received FDA PMA approval in June 2024, Stryker’s Contour Neurovascular System obtained CE Mark approval in May 2025, and Balt’s Silk Vista Baby flow diverter received FDA 510(k) clearance in February 2025. These approvals, alongside ongoing clinical trials, underscore a robust innovation pipeline targeting wide-neck, distal, and complex aneurysms.

Key Players

Leading intracranial aneurysm market players include Medtronic, Stryker, MicroPort Scientific Corporation, Johnson & Johnson Services, MicroVention Inc., B. Braun SE, Integra LifeSciences, RAUMEDIC AG, Terumo Corporation, Delta Surgical, Penumbra, Inc., Balt, Wallaby Medical, Shape Memory Medical Inc., Zylox-Tonbridge Medical Technology, Spartan Micro, Mizuho Medical, Lepu Medical Technology, Phenox GmbH, and Peter LAZIC GmbH.

Recent Developments

In May 2025, Stryker published a meta-analysis of 500 patients validating the safety and efficacy of the Contour Neurovascular System for wide-neck bifurcation aneurysms. In February 2025, Balt USA received FDA 510(k) clearance for the Silk Vista Baby flow diverter, expanding treatment options for small distal vessels and previously inaccessible aneurysms.

Future Outlook

The intracranial aneurysm market is set for sustained growth, fueled by technological innovation, rising disease prevalence, and increasing adoption of minimally invasive procedures. Investment in R&D, improved regulatory frameworks, and growing awareness among clinicians and patients will continue to support market expansion. Flow diverters, AI-driven detection tools, and robot-assisted interventions are expected to drive adoption further, while expanding access in emerging economies will broaden the market’s reach.

Other Trending Reports

Enteral Feeding Formulas Market

Narcolepsy Therapeutics Market

Bacterial & Viral Specimen Collection Market

Molecular Quality Controls Market